1. IDENTIFICATION OF THE SUBSTANCE/PREPARATION AND THE COMPANY/UNDERTAKING

Pfizer Inc
Pfizer Pharmaceuticals Group
235 East 42nd Street
New York, New York 10017
1-212-573-2222

Pfizer Ltd
Ramsgate Road
Sandwich, Kent
CT13 9NJ
United Kingdom
+00 44 (0)1304 616161

Emergency telephone number: CHEMTREC (24 hours): 1-800-424-9300
Contact E-Mail: pfizer-MSDS@pfizer.com

Material Name: Losartan Potassium Tablets

Trade Name: Not applicable
Chemical Family: Mixture
Intended Use: Pharmaceutical product used as Antihypertensive

2. HAZARDS IDENTIFICATION

Appearance: White Tablets
Signal Word: WARNING

Statement of Hazard: Suspected of damaging the unborn child.

Additional Hazard Information:
Short Term: Antihypertensive drug: has blood pressure-lowering properties
Long Term: Based on its pharmacologic properties and findings in animal studies, this compound may cause the use of this drugs may cause fetal and neonatal toxicity, including low blood pressure and kidney failure, when they are taken during the second and third trimesters of pregnancy.

Known Clinical Effects: Adverse effects associated with therapeutic use include dizziness, headache, lethargy, changes in blood pressure, nausea, abdominal pain, hypersensitivity reactions, impaired renal function, and potential liver toxicity in people with impaired liver function.

EU Indication of danger: Toxic to Reproduction: Category 3

EU Hazard Symbols: Xn

EU Risk Phrases: R63 - Possible risk of harm to the unborn child.


Note: This document has been prepared in accordance with standards for workplace safety, which require the inclusion of all known hazards of the product or its ingredients regardless of the potential risk. The precautionary statements and warnings included may not apply in all cases. Your needs may vary depending upon the potential for exposure in your workplace.
2. HAZARDS IDENTIFICATION

3. COMPOSITION/INFORMATION ON INGREDIENTS

<table>
<thead>
<tr>
<th>Ingredient</th>
<th>CAS Number</th>
<th>EU EINECS/ELINCS List</th>
<th>EU Classification</th>
<th>%</th>
</tr>
</thead>
<tbody>
<tr>
<td>Losartan potassium</td>
<td>124750-99-8</td>
<td>Not Listed</td>
<td>Repr.Cat.3;R63</td>
<td>25, 50, or 100 mg***</td>
</tr>
<tr>
<td>Microcrystalline cellulose</td>
<td>9004-34-6</td>
<td>232-674-9</td>
<td>Not Listed</td>
<td>*</td>
</tr>
<tr>
<td>Magnesium stearate</td>
<td>557-04-0</td>
<td>209-150-3</td>
<td>Not Listed</td>
<td>*</td>
</tr>
<tr>
<td>Lactose Monohydrate</td>
<td>64044-51-5</td>
<td>Not Listed</td>
<td>Not Listed</td>
<td>*</td>
</tr>
<tr>
<td>Starch, pregelatinised</td>
<td>9005-25-8</td>
<td>232-679-6</td>
<td>Not Listed</td>
<td>*</td>
</tr>
<tr>
<td>Hydroxypropyl cellulose</td>
<td>9004-64-2</td>
<td>Not Listed</td>
<td>Not Listed</td>
<td>*</td>
</tr>
<tr>
<td>Film coating</td>
<td>NOT ASSIGNED</td>
<td>Not Listed</td>
<td>Not Listed</td>
<td>*</td>
</tr>
</tbody>
</table>

Additional Information:  
* Proprietary  
Ingredient(s) indicated as hazardous have been assessed under standards for workplace safety.

For the full text of the R phrases mentioned in this Section, see Section 16

4. FIRST AID MEASURES

Eye Contact: Flush with water while holding eyelids open for at least 15 minutes. Seek medical attention immediately.

Skin Contact: Remove contaminated clothing. Flush area with large amounts of water. Use soap. Seek medical attention.

Ingestion: Never give anything by mouth to an unconscious person. Wash out mouth with water. Do not induce vomiting unless directed by medical personnel. Seek medical attention immediately.

Inhalation: Remove to fresh air and keep patient at rest. Seek medical attention immediately.

Symptoms and Effects of Exposure: For information on potential signs and symptoms of exposure, See Section 2 - Hazards Identification and/or Section 11 - Toxicological Information.

5. FIRE FIGHTING MEASURES

Extinguishing Media: Use carbon dioxide, dry chemical, or water spray.

Hazardous Combustion Products: Formation of toxic gases is possible during heating or fire.

Fire Fighting Procedures: During all fire fighting activities, wear appropriate protective equipment, including self-contained breathing apparatus.

Fire / Explosion Hazards: Not determined
6. ACCIDENTAL RELEASE MEASURES

Health and Safety Precautions: Personnel involved in clean-up should wear appropriate personal protective equipment (see Section 8). Minimize exposure.

Measures for Cleaning / Collecting: Contain the source of spill if it is safe to do so. Collect spilled material by a method that controls dust generation. A damp cloth or a filtered vacuum should be used to clean spills of dry solids. Clean spill area thoroughly.

Measures for Environmental Protections: Place waste in an appropriately labeled, sealed container for disposal. Care should be taken to avoid environmental release.

Additional Consideration for Large Spills: Non-essential personnel should be evacuated from affected area. Report emergency situations immediately. Clean up operations should only be undertaken by trained personnel.

7. HANDLING AND STORAGE

General Handling: Minimize dust generation and accumulation. If tablets or capsules are crushed and/or broken, avoid breathing dust and avoid contact with eyes, skin, and clothing. When handling, use appropriate personal protective equipment (see Section 8). Wash hands and any exposed skin after removal of PPE. Releases to the environment should be avoided. Review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure or environmental releases. Potential points of process emissions of this material to the atmosphere should be controlled with dust collectors, HEPA filtration systems or other equivalent controls.

Storage Conditions: Store as directed by product packaging.

8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Refer to available public information for specific member state Occupational Exposure Limits.

Microcrystalline cellulose

| ACGIH Threshold Limit Value (TWA) | 10 mg/m³ TWA |
| Australia TWA | 10 mg/m³ |
| Belgium OEL - TWA | Listed |
| Estonia OEL - TWA | Listed |
| France OEL - TWA | Listed |
| Ireland OEL - TWAs | Listed |
| Latvia OEL - TWA | Listed |
| OSHA - Final PELS - TWAs: | 15 mg/m³ total |
| | 5 mg/m³ |
| Portugal OEL - TWA | Listed |
| Romania OEL - TWA | Listed |
| Spain OEL - TWA | Listed |

Starch, pregelatinized

| ACGIH Threshold Limit Value (TWA) | 10 mg/m³ TWA |
| Australia TWA | 10 mg/m³ |
| Belgium OEL - TWA | Listed |
| Bulgaria OEL - TWA | Listed |
| Czech Republic OEL - TWA | Listed |
| Greece OEL - TWA | Listed |
| Ireland OEL - TWAs | Listed |
| OSHA - Final PELS - TWAs: | 15 mg/m³ total |
| | 5 mg/m³ |
8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Engineering Controls: Engineering controls should be used as the primary means to control exposures. General room ventilation is adequate unless the process generates dust, mist or fumes. Keep airborne contamination levels below the exposure limits listed above in this section.

Environmental Exposure Controls: Refer to specific Member State legislation for requirements under Community environmental legislation.

Personal Protective Equipment: Refer to applicable national standards and regulations in the selection and use of personal protective equipment (PPE).

- Hands: Impervious gloves are recommended if skin contact with drug product is possible and for bulk processing operations.
- Eyes: Wear safety glasses or goggles if eye contact is possible.
- Skin: Impervious protective clothing is recommended if skin contact with drug product is possible and for bulk processing operations.
- Respiratory protection: If the applicable Occupational Exposure Limit (OEL) is exceeded, wear an appropriate respirator with a protection factor sufficient to control exposures to below the OEL.

9. PHYSICAL AND CHEMICAL PROPERTIES

- Physical State: Tablets
- Molecular Formula: Mixture
- Color: No data available.
- Molecular Weight: Mixture
- Polymerization: Will not occur

10. STABILITY AND REACTIVITY

- Chemical Stability: Stable under normal conditions of use.
- Conditions to Avoid: Fine particles (such as dust and mists) may fuel fires/explosions.
- Incompatible Materials: As a precautionary measure, keep away from strong oxidizers

11. TOXICOLOGICAL INFORMATION

General Information: The information included in this section describes the potential hazards of the individual ingredients.
11. TOXICOLOGICAL INFORMATION

Acute Toxicity: (Species, Route, End Point, Dose)

Lactose Monohydrate
Rat Oral LD50 29700 mg/kg

Magnesium stearate
Rat Oral LD50 > 2000 mg/kg
Rat Inhalation LC50 > 2000 mg/m³

Microcrystalline cellulose
Rat Oral LD50 > 5000 mg/kg
Rabbit Dermal LD50 > 2000 mg/kg

Losartan potassium
Mouse Oral Minimum Lethal Dose 1000 mg/kg
Rat Oral Minimum Lethal Dose 2000 mg/kg

Acute Toxicity Comments: A greater than symbol (>) indicates that the toxicity endpoint being tested was not achievable at the highest dose used in the test.

Irritation / Sensitization: (Study Type, Species, Severity)

Microcrystalline cellulose
Skin Irritation Rabbit Non-irritating
Eye Irritation Rabbit Non-irritating

Reproduction & Developmental Toxicity: (Study Type, Species, Route, Dose, End Point, Effect(s))

Losartan potassium
Reproductive & Fertility Rat Oral 150 mg/kg/day NOAEL Maternal toxicity
Embryo / Fetal Development Rat No route specified 10 mg/kg/day LOAEL Neonatal toxicity, Fetotoxicity

Genetic Toxicity: (Study Type, Cell Type/Organism, Result)

Lactose Monohydrate
*In Vitro* Bacterial Mutagenicity (Ames) Negative

Losartan potassium
Bacterial Mutagenicity (Ames) *Salmonella*, *E. coli* Negative
Mammalian Cell Mutagenicity Not specified Negative
*In Vitro* Chromosome Aberration Not specified Negative
*In Vivo* Chromosome Aberration Not specified Negative

Carcinogenicity: (Duration, Species, Route, Dose, End Point, Effect(s))

Losartan potassium
105 Week(s) Rat Oral 270 mg/kg/day Maximally Tolerated Dose Not carcinogenic
92 Week(s) Mouse Oral 200 mg/kg/day Maximally Tolerated Dose Not carcinogenic

Carcinogen Status: None of the components of this formulation are listed as a carcinogen by IARC, NTP or OSHA.
12. ECOLOGICAL INFORMATION

Environmental Overview: The environmental characteristics of this material have not been fully evaluated. Releases to the environment should be avoided.

13. DISPOSAL CONSIDERATIONS

Waste Treatment Methods: Dispose of waste in accordance with all applicable laws and regulations. Member State specific and Community specific provisions must be considered. Considering the relevant known environmental and human health hazards of the material, review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure and environmental release. It is recommended that waste minimization be practiced. The best available technology should be utilized to prevent environmental releases. This may include destructive techniques for waste and wastewater.

14. TRANSPORT INFORMATION

Not regulated for transport under USDOT, EUADR, IATA, or IMDG regulations.

15. REGULATORY INFORMATION

EU Symbol: Xn
EU Indication of danger: Toxic to Reproduction: Category 3

EU Risk Phrases: R63 - Possible risk of harm to the unborn child.

EU Safety Phrases: S22 - Do not breathe dust.
S36/37 - Wear suitable protective clothing and gloves.

OSHA Label:
WARNING
Suspected of damaging the unborn child.

Canada - WHMIS: Classifications

WHMIS hazard class:
Class D, Division 2, Subdivision A

Microcrystalline cellulose
Inventory - United States TSCA - Sect. 8(b) Listed
Australia (AICS): Listed
15. REGULATORY INFORMATION

<table>
<thead>
<tr>
<th>Material Name</th>
<th>EU EINECS/ELINCS List</th>
<th>Australia (AICS):</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lactose Monohydrate</td>
<td></td>
<td>Listed</td>
</tr>
<tr>
<td>Starch, pregelatinized</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inventory - United States TSCA - Sect. 8(b)</td>
<td>Listed</td>
<td></td>
</tr>
<tr>
<td>Australia (AICS):</td>
<td></td>
<td>Listed</td>
</tr>
<tr>
<td>REACH - Annex IV - Exemptions from the obligations of Register:</td>
<td></td>
<td>Present</td>
</tr>
<tr>
<td>EU EINECS/ELINCS List</td>
<td>232-674-9</td>
<td></td>
</tr>
<tr>
<td>Hydroxypropyl cellulose</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inventory - United States TSCA - Sect. 8(b)</td>
<td>Listed</td>
<td></td>
</tr>
<tr>
<td>Australia (AICS):</td>
<td></td>
<td>Listed</td>
</tr>
<tr>
<td>Magnesium stearate</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inventory - United States TSCA - Sect. 8(b)</td>
<td>Listed</td>
<td></td>
</tr>
<tr>
<td>Australia (AICS):</td>
<td></td>
<td>Listed</td>
</tr>
<tr>
<td>EU EINECS/ELINCS List</td>
<td>209-150-3</td>
<td></td>
</tr>
</tbody>
</table>

16. OTHER INFORMATION

Text of R phrases mentioned in Section 3

R63 - Possible risk of harm to the unborn child.

Data Sources: Publicly available toxicity information. Safety data sheets for individual ingredients.

Reasons for Revision: Updated Section 11 - Toxicology Information.

Prepared by: Product Stewardship Hazard Communications
             Pfizer Global Environment, Health, and Safety Operations

Pfizer Inc believes that the information contained in this Material Safety Data Sheet is accurate, and while it is provided in good faith, it is without warranty of any kind, expressed or implied. If data for a hazard are not included in this document there is no known information at this time.

End of Safety Data Sheet